Evidence map›Paper›PMID 42796727›Full record

ArticlePathogens (Basel, Switzerland)2026

A Two-Phase Approach to the Use of Tafenoquine Was Associated with Cure of Babesiosis in Two Immunocompromised Patients with Relapsing Babesiosis.

Nonso Osakwe, Gary P Wormser

Abstract readCase Reports
In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Nonso OsakweDepartment of Medicine, Division of Infectious Diseases, Northern Westchester Hospital-Northwell Health, Mount Kisco, NY 10549, USA.
Gary P WormserDepartment of Medicine, Division of Infectious Diseases, New York Medical College, Valhalla, NY 10595, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two immunocompromised patients with relapsing babesiosis were cured using a well-tolerated course of tafenoquine (171 and 212 days, respectively), with negative polymerase chain reactivity intentionally exceeding the 120-day lifespan of erythrocytes before discontinuing the tafenoquine. During the first 10 days of tafenoquine both patients also received an atovaquone-containing drug regimen. This was prescribed based on the demonstrated benefit of atovaquone on the efficacy of tafenoquine for completely eradicating

Indexed as

AminoquinolinesAntiprotozoal AgentsBabesia microtiBabesiosisImmunocompromised HostAgedAnimalsAtovaquoneDibenzocycloheptenesFemaleHumansMaleMiddle AgedRecurrenceTreatment OutcomeAminoquinolinesAntiprotozoal AgentsAtovaquoneDibenzocycloheptenestafenoquineBabesia microtibabesiosisimmunocompromisedtafenoquine

Identifiers

PMID42796727
PMCPMC13610489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.